Med Life (BSE:M) ROCE %: 7.36% (As of Mar. 2026)


BSE:M Med Life SA BSE:M
90 GF Score
Price lei11.36
GF Value lei7.82
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is Med Life ROCE %?

Med Life BSE:M +0.53% 90 ROCE % is 7.36% as of Mar. 2026. GuruFocus rates BSE:M with a GF Score™ of 90/100 and a GF Value™ of lei7.82 (Significantly Overvalued). The stock has 4 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Med Life's annualized ROCE % for the quarter that ended in Mar. 2026 was 7.36%.

Med Life  (BSE:M) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Med Life ROCE % Related Terms

Med Life ROCE % Historical Data

* Premium members only.

The historical data trend for Med Life's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Med Life ROCE % Chart

Med Life Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
ROCE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 12.89 16.77 6.50 4.59 6.95

Med Life Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Mar26
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.29 7.63 0.98 6.11 7.36
BSE:M
90GF Score
Med Life SA BSE:M
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Med Life ROCE % Calculation

Med Life's annualized ROCE % for the fiscal year that ended in Dec. 2024 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Dec. 2024 )  (A: Dec. 2023 )(A: Dec. 2024 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Dec. 2024 )  (A: Dec. 2023 )(A: Dec. 2024 )
=138.286/( ( (2636.337 - 699.674) + (3022.348 - 977.49) )/ 2 )
=138.286/( (1936.663+2044.858)/ 2 )
=138.286/1990.7605
=6.95 %

Med Life's ROCE % of for the quarter that ended in Mar. 2026 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Mar. 2026 )  (Q: Sep. 2025 )(Q: Mar. 2026 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Mar. 2026 )  (Q: Sep. 2025 )(Q: Mar. 2026 )
=172.432/( ( (3142.851 - 862.786) + (3335.797 - 929.699) )/ 2 )
=172.432/( ( 2280.065 + 2406.098 )/ 2 )
=172.432/2343.0815
=7.36 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of 7.36% mean?
Med Life (BSE:M) has a ROCE % of 7.36% as of Mar. 2026.
Is Med Life's ROCE % too high?
Med Life's current ROCE % is 7.36%. The Healthcare Providers & Services industry median ROCE % is 6.41. Med Life's value of 7.36% is 14.8% above this industry median. Overall, Med Life has a GF Score™ of 90/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Med Life's ROCE % compare to HCA and THC?
Med Life's ROCE % of 7.36% can be compared against companies in the Healthcare Providers & Services industry. The industry median ROCE % is 6.41. Med Life's value of 7.36% is 14.8% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Healthcare Providers & Services company?
The median ROCE % among Healthcare Providers & Services companies is 6.41, based on 648 companies in the industry. Companies in the top quartile (top 25%) have a ROCE % significantly above this median, while those in the bottom quartile fall well below. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Med Life's current ROCE % of 7.36% is 14.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. For the Healthcare Providers & Services industry, the median ROCE % is 6.41 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Med Life's current ROCE % is 7.36%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Med Life stock overvalued right now?
Based on GuruFocus' analysis, Med Life (BSE:M) is currently considered Significantly Overvalued. The stock's GF Value™ is lei7.82, compared to a current price of lei11.36 — trading 45.3% above its estimated fair value. The current ROCE % is 7.36% and 14.8% above the Healthcare Providers & Services industry median of 6.41. Med Life's overall GF Score™ is 90/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For Med Life (BSE:M), the current ROCE % is 7.36% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Med Life (BSE:M) Overvalued in 2026?

Based on GuruFocus' analysis, Med Life stock appears to be overvalued. The current stock price of lei11.36 is trading 45.3% above its estimated GF Value™ of lei7.82. GuruFocus considers Med Life to be Significantly Overvalued.

Key valuation signals for BSE:M:

  • ROCE %: 7.36%
  • GF Value™: lei7.82 vs. price of lei11.36 (45.3% above fair value)
  • GF Score™: 90/100 with 4 warning signs
  • Industry Position: 14.8% above the Healthcare Providers & Services median

No single metric tells the full story. See the BSE:M stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Med Life Business Description

Other Exchanges 0RO5:UKO0C:Germany
Address Calea Grivitei, No. 365, District 1, Bucharest, ROU
Med Life SA is a healthcare provider in Romania. The Company's activity resides in the performance of healthcare services activities through medical centres with national coverage. It is engaged in the provision of rendering of medical services, rental of medical facilities and acquisition of materials and commodities. The company provides medical service through Hyper clinics in Arad, Bucharest, Braila, Brasov, Cluj, Constanta, Craiova, Galati, Iasi, Oradea, Ploiesti, Sibiu and Timisoara; Clinics, hospitals located in Bucharest, Arad, Sibiu, Brasov, Cluj and Ploiesti, Laboratories, Pharmacies and Dental Clinics.
90GF Score

Get the complete analysis for BSE:M

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

lei11.36
Price
lei7.82
GF Value